Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
79 results about "Hypoglycemic Medicines" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Sulfonylureas remain the most widely prescribed drugs for treating hyperglycemia. The meglitinide analog repaglinide and the D-phenylalanine derivative nateglinide also bind the sulfonylurea receptor and stimulate insulin secretion. (2) Drugs that alter insulin action: Metformin works in the liver.
Stable pharmaceutical composition of immediate-release glimepiride and extended-release metformin
InactiveUS20070264331A1Avoid mixingBiocideMetabolism disorderImmediate releaseMetformin Hydrochloride
This invention is directed to a pharmaceutical composition in the form of a tablet with improved stability, as well as the process for obtaining said composition. The tablet of the present invention comprises two active ingredients comprising two oral hypoglycemic agents: one phase with a sulphonylurea, such as immediate release Glimepiride, and a second phase with a biguanide, such as extended-release Metformin hydrochloride (Metformin HCl). The biphasic tablet, which can include over 500 mg of Metformin HCl (i.e. up to 1,000 or 1,500 mg, depending on the daily requirements of each patient), is to be orally administered once or twice a day. The combination of these hypoglycemic agents has a synergic effect and therefore a greater effectiveness in controlling the blood glucose level in patients with diabetes mellitus, type 2.
Owner:LAB SILANES
Hepatocyte growth factor for treatment of diabetes
InactiveUS6472366B2Lower blood sugar levelsLower Level RequirementsBiocidePeptide/protein ingredientsCvd riskBULK ACTIVE INGREDIENT
The present invention provides a therapeutic agent for treatment of diabetes and hyperlipemia, especially a therapeutic agent for treatment of type II diabetes mellitus, which comprises as the active ingredient a neurotrophic factor such as BDNF (brain-derived neurotrophic factor), ligands of trkB or trkC receptors, NGF, NT-3, NT-4 / 5, CNTF, GDNF, HGF, etc. Different from conventional oral hypoglycemic agents being mainly used in the treatment of type II diabetes mellitus, the agent of the present invention exhibit blood lipid regulating effects and body fat accumulation regulating effects, in addition to the blood glucose regulating effects. Thus, the agent of the present invention are novel, and can reduce the risk factors in diabetes accompanied by hyperlipemia or obesity, without using any other agent.
Owner:SUMITOMO PHARMA CO LTD
Mango aglycone, preparation purification process and uses thereof
InactiveCN101367787AGood reproducibilityHigh yieldOrganic active ingredientsOrganic chemistryPurification methodsCarbon–carbon bond
The present invention belongs to the technical field of biological pharmacy, and in particular relates to a preparation and purification method of tetra-hydroxyl xanthone mango aglycone (norathyriol), and an application thereof in hypoglycemic medicine. Based on biological experiments, mango glycoside is used as raw material; under the condition with phenol and hydroiodic acid, carbon-carbon bonds are broken to produce the crude product of mango aglycone; the crude product is separated and purified through silica gel column chromatography so that the mango aglycone is separated; the yield rate reaches 12 percent, the purity is higher than 95 percent, and the reproduction performance is good; the IGTT of C57BL / 6 normal mice is effectively improved with the norathyriol; and simultaneously the quantity of insulin secretion induced by glucose in vivo for the C57BL / 6 normal mice can be improved with the norathyriol. Therefore, the mango aglycone can be applied for preparation of hypoglycemic medicine.
Owner:NANJING UNIV
Remedies for diabetes
InactiveUS6391312B1Improve securityBlood glucose level of was not reducedPeptide/protein ingredientsPeptide preparation methodsCvd riskBULK ACTIVE INGREDIENT
The present invention provides a therapeutic agent for treatment of diabetes and hyperlipemia, especially a therapeutic agent for treatment of type II diabetes mellitus, which comprises as the active ingredient a neurotrophic factor such as BDNF (brain-derived neurotrophic factor), ligands of trkB or trkC receptors, NGF, NT-3, NT-4 / 5, CNTF, GDNF, HGF, etc. Different from conventional oral hypoglycemic agents being mainly used in the treatment of type II diabetes mellitus, the agent of the present invention exhibit blood lipid regulating effects and body fat accumulation regulating effects, in addition to the blood glucose regulating effects. Thus, the agent of the present invention are novel, and can reduce the risk factors in diabetes accompanied by hyperlipemia or obesity, without using any other agent.
Owner:SUMITOMO DAINIPPON PHARMA CO LTD
Compounded medicine for wholely preventing and treating cardio-cerebral blood vessel diseases and use thereof
InactiveCN101024082ASmall doseLittle side effectsPharmaceutical delivery mechanismOil/fats/waxes non-active ingredientsDiseaseSide effect
The present invention relates to a compound medicine for preventing and curing angiocardiopathy and cerebrovascular disease, belonging to the field of chemical medicine. It is characterized by that said compound medicine includes sexual hormones medicine, lipid-reducing medicine, hypotenser, hypoglycemic medicine and anticoagulant medicine. Said compound medicine can be made into various dosage forms. Besides, said compound medicine also can be used for curing the diseases of climacteric syndrome, osteoporosis, endometrial carcinoma, diabetes and metabolic syndrome, etc.
Owner:张士东
Hypoglycemic medicine
The invention relates to a hypoglycemic medicine and a composition, and in particular relates to a compound as shown in the formula I or a solvate thereof. The structure of the composition is described in the specification. The invention further relates to a medicine composition comprising the compound and application of the medicine composition and the compound. The compound or the composition is an excellent hypoglycemic medicine.
Owner:北京凯利丰经贸有限公司
Traditional Chinese medicine capsule for repairing dysinsulinism function to balance blood sugar
InactiveCN101306171APromote blood circulationImprove nutritional statusMetabolism disorderCapsule deliveryAdditive ingredientRadix Rehmanniae Preparata
The invention relates to a Chinese traditional hypoglycemic medicine, in particular a thirty-ingredient hypoglycemic gelatin capsule, which is prepared from thirty ingredients, including red ginseng, astragali, ganoderma lucidum, magnolia vine fruit, kudzu root, radix salviae miltiorrhizae, hemlock parsley, symbranchoid eels, dodder, black sesame seed, radix rehmanniae, radix rehmanniae preparata, blackfungus and so on, through extraction.
Owner:王跃进
2,3,5,4'-tetrahydroxy diphenyl ethylene-2-1-beta-d-glucoside
InactiveCN1539844AGood water solubilityReduce dissolutionOrganic active ingredientsSugar derivativesBeta-DLipoprotein cholesterol
A 2,3,5,4'-tetrahydroxy distyrene-2-O-beta-D-glucoside used for hypoglycemic medicine is prepared from the decoction of fleece flower root through extracting, separating and purifying. It can suppress the increasement of serum cholesterol, decrease low-density serum lipoprotein cholesterol and improve activity of liver esterase.
Owner:广州中医药大学热带医学研究所
Sugar-lowering drug composition and application thereof
ActiveCN101897696AAlleviate elevated plasma homocysteineEffective blood sugar controlSenses disorderNervous disorderTreatment effectThiazolidinedione
The invention relates to a sugar-lowering drug composition and application thereof. The composition comprises 1) medicinal dosage of vildagliptin, 2) medicinal dosage of any one or combination of thiazolidinedione sugar-lowering drugs or medicinal salt thereof, sulfonylurea sugar-lowering drugs or medicinal salt thereof or biguanide sugar-lowering drugs or medicinal salt thereof and 3) B vitamins. The invention relates to application of the sugar-lowering drug composition to preparing the drugs for treating and / or controlling diabetes or diabetic complications. The composition can effectively overcome the defect that type 2 diabetes can not be controlled by singly taking the commonly used sugar-lowering drugs or vildagliptin in the prior art and simultaneously addition of the B vitamins is conductive to enhancing the treatment effect of the drug, effectively controlling the blood sugar, protecting the endothelial cell functions in a synergic manner, slowing rising of plasma homocysteine of the diabetes patients, especially the diabetes patients associated with chronic complications and reducing the diabetic complications.
Owner:深圳市奥萨制药有限公司 +2
Hypoglycemic medicine composition
InactiveCN101103993AAlleviate elevated plasma homocysteineEffective blood sugar controlPowder deliveryMetabolism disorderThiazolidinedioneB Vitamin Family
The invention relates to a newly-developed medicine compound for diabetes which contains sulfonylureas drug for diabetes or a bioactive metabolite of the sulfonylureas drug for diabetes or pharmaceutical salt of the sulfonylureas drug for diabetes, and thiazolidinedione drug for diabetes or pharmaceutical salt and vitamin B of the thiazolidinedione drug for diabetes. The compound contains the sulfonylureas drug for diabetes of therapy dose or the bioactive metabolite of the sulfonylureas drug for diabetes or the pharmaceutical salt of the sulfonylureas drug for diabetes, the thiazolidinedione drug for diabetes of therapy dose or the pharmaceutical salt and therapy dose of vitamin B of the thiazolidinedione drug for diabetes or compound which is related to the thiazolidinedione drug for diabetes and has similar bioactivity and pharmaceutical carrier or excipient. The invention also relates to the purpose of the compound in preparation of drug for treating diabetes or preventing diabetes complication, belonging to the pharmaceutical field.
Owner:SHENZHEN AUSA PHARMA
Therapeutic agent for treatment of diabetes
InactiveUS20020122829A1Lower blood sugar levelsLower Level RequirementsPeptide/protein ingredientsMetabolism disorderTherapeutic effectCvd risk
The present invention provides a therapeutic agent for treatment of diabetes and hyperlipemia, especially a therapeutic agent for treatment of type II diabetes mellitus, which comprises as the active ingredient a neurotrophic factor such as BDNF (brain-derived neurotrophic factor), ligands of trkB or trkC receptors, NGF, NT-3, NT-4 / 5, CNTF, GDNF, HGF, etc. Different from conventional oral hypoglycemic agents being mainly used in the treatment of type II diabetes mellitus, the agent of the present invention exhibit blood lipid regulating effects and body fat accumulation regulating effects, in addition to the blood glucose regulating effects. Thus, the agent of the present invention are novel, and can reduce the risk factors in diabetes accompanied by hyperlipemia or obesity, without using any other agent.
Owner:SUMITOMO DAINIPPON PHARMA CO LTD
Kidney benefiting hypoglycemic medicine composition and its prepn process
InactiveCN1846765ADefense treatment cycle is shortImprove immunityMetabolism disorderInanimate material medical ingredientsToxic materialBlood sugar
The present invention relates to kidney benefiting hypoglycemic medicine composition and its preparation process. The kidney benefiting hypoglycemic medicine composition is prepared with 31 kinds of Chinese medicinal materials, including angelica, ginseng, figwort, beach silvertop root, Chinese yam, etc. and through washing, stoving, crushing, sieving and other steps. It has the functions of nourishing lung and kidney, clearing away stomach heat, tranquilizing, clearing away heat and toxic material and reducing blood sugar. It can also remit complication and strengthen immunity.
Owner:王利芳
Application of sea collagen peptide as preparation of hypoglycemic medicine, health-care food or food
InactiveCN101167753APromote absorptionGood water solubilityPowder deliveryPeptide/protein ingredientsAcute hyperglycaemiaSolubility
The invention discloses a use of ocean collagen peptide used in preparation of blood-glucose medicine, hypoglycemic health food or hypoglycemic food, which is characterized by high absorption, fast absorption, low viscosity, and good water-solubility etc. Experiment proves that the ocean collagen peptide given to a little mouse can lower alloxan hyperglycosemia of fasting blood-glucose level of a big mouse. Meanwhile, sugar tolerance of a hyperglycemia big mouse is improved, which indicates that the ocean collagen peptide has hypoglycemic action.
Owner:珍奥集团股份有限公司
Intelligent diabetes peripheral neuropathy treatment instrument
InactiveCN108553257AReminder to takeEasy to useElectrotherapyOperating chairsPeripheral neuropathyBlood vessel
The invention discloses an intelligent diabetes peripheral neuropathy treatment instrument. The treatment instrument comprises a treatment instrument body. The treatment instrument can help patients in detecting blood glucose and blood pressure, and the blood pressure and the blood glucose can be detected at will to remind the patients to take hypotensive and hypoglycemic medicines; the patients can be treated by sitting or laying, and the height of a seat can be adjusted to facilitate the getting on and off of the patients; massage can be conducted on the backs and hips of the patient to prevent long-term body paralysis and increase treating time, and the patients can be massaged while treated; caring is conducted on feet through a manner of medicine bathing and magnetic treatment, through the manner of medicine bathing and magnetic treating, the patients have health-caring effects, and the flowing of blood can be accelerated to prevent blood vessel pathological changes; treatment ofthe patients is conducted through a drug fumigation manner to improve the effect of traditional Chinese medicines so that the patients suffered from diabetes can accept treatments of multiple mannersto prevent pathological changes; the instrument is suitable for caring of the patients at home to prevent the peripheral neuropathy of the patients, and convenience is brought for the patients.
Owner:THE FIRST AFFILIATED HOSPITAL OF MEDICAL COLLEGE OF XIAN JIAOTONG UNIV
Method for bioremediating waste water containing copper by common dayflower
InactiveCN101560018ABeautify the body of waterBiocidePlant growth regulatorsPhytoremediationPollution
The invention relates to phytoremediation technology for treating heavy metal waste water, in particular to a remediating method of heavy metal waste water containing copper by synergistic action of commelinaceae plant and microorganic microbial inoculum. A biological floating bed made from common dayflower is put in waste water polluted by copper which is added with a probiotic agent, pollution by copper is removed by absorption and enrichment of the plant on heavy metal copper, the action of the microbial inoculum is to antagonize putrefying bacteria and secretes auxin substance to improve the biomass of common dayflower, and the harvested common dayflower is used as a raw material for extracting hypoglycemic medicine deoxynojirimycin (shortened as DNJ), thus the remediating process becomes the process of managing pollution, beautifying the environment and obtaining DNJ raw material.
Owner:CHANGSHU NANJING NORMAL UNIV DEV RES INST
Sugar-lowering drug composition and application
InactiveCN101897697AProtective functionReduce complicationsSenses disorderNervous disorderSulfonylureaThiazolidinedione
The invention relates to a sugar-lowering drug composition and application thereof. The composition comprises 1) medicinal dosage of vildagliptin and 2) medicinal dosage of any one or combination of thiazolidinedione sugar-lowering drugs or medicinal salt thereof, sulfonylurea sugar-lowering drugs or medicinal salt thereof and biguanide sugar-lowering drugs or medicinal salt thereof. The invention relates to application of the sugar-lowering drug composition to preparing the drugs for treating and / or preventing diabetes or diabetic complications. The composition can effectively overcome the defect that type 2 diabetes can not be controlled by singly taking the commonly used sugar-lowering drugs or vildagliptin in the prior art and can reduce the diabetic complications.
Owner:北京奥萨医药研究中心有限公司 +1
Method for rapidly detecting sulfonylomocznik compound added in hypoglycemic health foods, Chinese patent medicines and foodstuff and applications thereof
InactiveCN103645179AFast detection methodMeet the needs of supervision and inspectionMaterial analysis by observing effect on chemical indicatorWater bathsLiquid layer
The invention provides a Method for rapidly detecting a sulfonylomocznik compound added in hypoglycemic medicines, health products and foodstuff and applications thereof. The method comprises selecting a tested sample of once taking amount, adding 3ml dichloromethane, shaking out to dissolve, stewing for a moment, and filtrating; selecting 2ml of filtrate, adding 10mg or 20mg of vanillin solid , then adding 2ml of concentrated sulfuric acid solution, heating for 1min in a micro boiling water bath until an upper dichloromethane layer is completely volatilized; and cooling the solution to room temperature, slowly adding 5ml of ethanol, immediately observing color change of a liquid separation layer and an upper layer solution, slightly shaking up if the liquid separating layer changes purple, and determining that sulfonylomocznik compound is added when the liquid separation layer and the upper layer solution change blue. The method and a used kit have advantages of low analysis cost, strong anti-interference capability, no need of special equipment, high sensitivity, obvious easy observation and judgement of chromogenic result, and high correct rate of examination conclusion, and are suitable for on-site rapid detection.
Owner:江苏省食品药品检验所 +2
Traditional Chinese medicine healthcare product for reducing blood sugar
The invention relates to a traditional Chinese medicine healthcare product for reducing blood sugar. The traditional Chinese medicine healthcare product comprises 10-15 parts of Chinese yarn, 10-20 parts of astragalus membranaceus, 8-15 parts of common peony roots, 10-15 parts of kudzu vine roots, 8-15 parts of corn stigma, 8-15 parts of polygonatum odoratum, 6-10 parts of lycium barbarum, 10-15 parts of cocklebur fruit, 6-10 parts of angelica sinensis, 6-10 parts of cortex lycii radicis, 6-10 parts of bitter gourds and 6-10 parts of smoked plums. A traditional Chinese medicine healthcare product is prepared from the following traditional Chinese raw material medicines in parts by weight: 12 parts of Chinese yam, 18 parts of astragalus membranaceus, 12 parts of common peony roots, 12 parts of kudzu vine roots, 10 parts of corn stigma, 10 parts of polygonatum odoratum, 8 parts of lycium barbarum, 12 parts of cocklebur fruits, 8 parts of angelica sinensis, 8 parts of cortex lycii radicis, 8 parts of bitter gourds and 8 parts of smoked plums. The invention adopts the traditional Chinese medicine and modern preparation techniques and relates to the traditional Chinese medicine healthcare product for reducing blood sugar. Due to the adoption of the traditional Chinese medicine and modern preparation techniques, blood vessel garbage can be cleaned away, the blood sugar concentration can be effectively reduced, the thirst symptom can be alleviated, and the traditional Chinese medicine healthcare product can be used together with hypoglycemic medicines for treatment.
Owner:SHAANXI KANGLE TRADITIONAL CHINESE MEDICINE HEALTH MAINTENANCE RES INST
Composition containing sugar-reducing medicine and antiplatelet medicine
The present invention relates to a medicine composition containing hypoglycemic medicine (mainly including thiazolidione, biquanide or alpha-glycosidase inhibitor) and antiplatelet medicine (mainly including aspirin or clopidogrel). Said medicine composition contains hypoglycemic medicine or its medicinal salt with effective dose and medicinal carrier or excipient. Said invention also provides the application of said medicine composition in preparation of medicine for curing the diseases of hypertension, diabetes, inflammation and atherosclerosis, etc.
Owner:深圳市奥萨药业有限公司
Novel method of producing repaglinide key intermediate
InactiveCN101153010AHigh reaction safetyFew reaction stepsOrganic compound preparationCarboxylic acid esters preparationBenzoic acidPhenylacetic acid
The present invention relates to a method of preparing 4-ethoxycarbonyl-3-ethoxy phenylacetic acid. In a ether solvent, the 4-bromomethyl-2-ethoxy-benzoic acid ethyl ester and metal magnesium react at a certain temperature to produce Gers agent preparation of the compound. Without treatment, the reagent is directly dropped into dry ice. At last, a key intermediate 4-ethoxycarbonyl-3-ethoxy phenylacetic acid for preparation of repaglinide can be separated through hydrolysis.
Owner:BEIJING D VENTUREPHARM TECH DEV
Novel alpha-glucosidase active inhibitor
ActiveCN104906264AInhibits α-glucosidase activityOrganic active ingredientsMetabolism disorderFood additiveAlpha-glucosidase activity
The invention discloses a novel alpha-glucosidase active inhibitor, belonging to the field of functional factors of functional foods and medicines; tea pigments in the invention can be used for strongly inhibiting alpha-glucosidase activity; the IC50 of alcohol-soluble theaflavin, the IC50 of thearubigin and the IC50 of theabrownin are 3.94 mu g / ml, 3.24 mu g / ml and 75.43 mu g / ml respectively; the half inhibition rate IC 50 of alcohol-soluble theaflavin, the half inhibition rate IC50 of thearubigin and the half inhibition rate IC50 of theabrownin are 8.19 mu g / ml, 4.50 mu g / ml and 6.98 mu g / ml respectively; the alpha-glucosidase inhibition effect of alcohol-soluble tea pigments or water-soluble tea pigments is far prior to that of the common hypoglycemic medicine, namely acarbose (acarbose IC50=1.04 mg / ml); and therefore, the novel alpha-glucosidase active inhibitor can be used as a food additive or a medicine for treating diabetes. Because of being pure natural pigments extracted from tea leaves, the tea pigments are safe, nontoxic and better in blood sugar decreasing effect; the advantages of the tea pigments are imponderable by acarbose; and therefore, the novel alpha-glucosidase active inhibitor has the application prospect for being developed into a health-care product or a novel hypoglycaemic medicine.
Owner:南通励成生物技术有限公司
Dai medicine extract with hypoglycemic effect, preparation and application thereof
The invention discloses a Dai medicine extract with a hypoglycemic effect, preparation and application thereof. The Dai medicine extract is extracted from the Dai medicines Dischidia minor (Vahl.) Merr., Aspidopterys obcordata Hemsl., Passiflora wilsonii Hemsl., and Clerodendrum japonicum (Thunb.) Sweet. The invention also discloses a preparation method of the extract, and also discloses application of the extract and its medicinal composition as medicines and health care products, especially application in preparation of hypoglycemic medicines and health care products.
Owner:张宁
Mulberry resource long-acting hypoglycemic medicine composition as well as granules and preparation method thereof
InactiveCN104474026AReduce releaseReduce absorptionMetabolism disorderGranular deliveryBiotechnologyMicrobial transglutaminase
The invention discloses a mulberry resource long-acting hypoglycemic medicine composition as well as granules and a preparation method thereof. The mulberry resource long-acting hypoglycemic medicine composition comprises a mulberry resource hypoglycemic activity extract, a pueraria root flavonoid extract, gelatin and microbial transglutaminase; and the preparation method of the mulberry resource long-acting hypoglycemic granules comprises the following steps: preparing the mulberry resource hypoglycemic activity extract, preparing the pueraria root flavonoid extract, preparing the hypoglycemic granules, and the like. The mulberry resource hypoglycemic medicine composition and the granules prepared by using the method disclosed by the invention can be used for controlling the level of postprandial blood sugar in multi-way and long-acting modes.
Owner:SOUTHWEST UNIVERSITY
Effective hypoglycemic component of may flower and preparation method and use thereof
InactiveCN101406498AStrong inhibitory activityWidely distributed and readily availableOrganic active ingredientsMetabolism disorderFiltrationUrsolic acid
The invention discloses a hypoglycemic effective position for sweet osmanthus, a preparation method and application thereof. The effective position is an ethyl acetate position and / or a normal butanol position which is obtained by taking sweet osmanthus as a raw material, and after extraction of condensate by crushing, cold soaking, filtration and vacuum recovery. The hypoglycemic effective position, namely ethyl acetate extract, has obvious activity in inhibiting alpha-glucosaccharase; and hypoglycemic effective constituents obtained from the effective position, namely an ursolic acid and an oleanolic acid, also have high activity in inhibiting the alpha-glucosaccharase, wherein the IC50 value (the half inhibition ratio) is 0.003Mug.m L <-1>, and the activity of the ursolic acid and the oleanolic acid in inhibiting the alpha-glucosaccharase is better than that of a hypoglycemic medicine - acarbose (the IC50 value is 1,081.27 Mug.m L <-1>) which is commonly used on clinic under the same condition.
Owner:HENAN UNIVERSITY
Application of plukenetia volubilis linneo leaf extract to preparation of hypoglycemic medicines
InactiveCN106074671AThe effect is stable and peacefulLower blood sugar levelsMetabolism disorderPlant ingredientsWestern medicineSide effect
The invention discloses an application of a plukenetia volubilis linneo leaf extract to preparation of hypoglycemic medicines. An extraction method of the plukenetia volubilis linneo leaf extract comprises the following steps: taking plukenetia volubilis linneo leaves, adding a solvent, carrying out decoction and extraction, filtering an extracting solution and carrying out concentration. The effects of the plukenetia volubilis linneo leaves are focused, and the natural plant extract is adopted, thus avoiding the toxic and side effects of western medicines on human bodies. The extraction method is simple and practicable and is flexible in mode. The plukenetia volubilis linneo leaf extract belongs to plant extracts, has stable and gentle effects, does not have obvious toxic or side effect temporarily and avoids the defect that the traditional western medicines intensify the sequelae of diabetes mellitus while giving play to the hypoglycemic effects. Mice tests are carried out on the plukenetia volubilis linneo leaf extract and the research results show that 50mg / kg.BW dose of plukenetia volubilis linneo leaf extract has the effect of obviously reducing the blood glucose levels of human bodies, inferring that the plukenetia volubilis linneo leaves contain hypoglycemic functional components.
Owner:杜冰 +1
Novel NIDDM regimen
The present invention relates to the use of a short-acting oral hypoglycemic agent and to a novel regimen in the treatment of type 2 diabetes in which the endogenous secretion of insulin is stimulated in connection with meals by administering in connection with the meals a short-acting oral hypoglycaemic agent. Also, the present invention relates to a method of achieving significantly improvement in the glycaemic control by a combined use of repaglinide and metformin in NIDDM patients poorly controlled on metformin alone.
Owner:HEMMINGSEN LISBETH TOFTE +1
Hypoglycemic medicine for treating diabetes and its prepn process
InactiveCN1846758AThe effect of hypoglycemic treatment is obviousNo side effectsMetabolism disorderCapsule deliverySide effectCurative effect
The present invention is one kind of botanical hypoglycemic medicine for treating type-II diabetes and its preparation process. The botanical hypoglycemic medicine is prepared with cassia and waternut in the weight ratio of 0.8-1.2 to 3.5-4.5. The preparation process include the following steps: preparing fine cassia powder, extracting volatile cassia oil, preparing fine waternut powder, mixing, pelletizing and encapsulating or preparing oral liquid. The botanical hypoglycemic medicine has determined hypoglycemic effect, no obvious side effect and other advantages.
Owner:湖北省应城市人民医院
Traditional Chinese medicine composition for treating diabetes and preparation method thereof
InactiveCN103989996ANormal metabolismRegulate endocrineMetabolism disorderInanimate material medical ingredientsDiseaseSide effect
The invention discloses a traditional Chinese medicine composition for treating diabetes. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 25-35 parts of astragalus membranaceus, 20-30 parts of white peony root , 15-20 parts of rhizoma anemarrhenae, 12-16 parts of poria cocos, 12-16 parts of polygonatum kingianum , 5-10 parts of radix ophiopogonis, 5-10 parts of sedum verticallatum, 5-10 parts of euphorbia humifusa, 5-10 parts of Chinese ixora flower, 5-10 parts of Chinese trumpet creeper, 5-10 parts of caulis bambusae in taeniis, 4-8 parts of dens draconis, 4-8 parts of rabdosia rubescens, 3-6 parts of caulis kadsurae and 8-10 parts of liquorice. The invention discloses a preparation method of the traditional Chinese medicine composition. The traditional Chinese medicine composition for treating diabetes disclosed by the invention is pure traditional Chinese medicine preparation, has a remarkable curative effect and not obvious toxic and side effect on diabetes caused by endocrine dyscrasia, can be used for overcoming the problems that the conventional medicament for treating the diabetes is high in use amount of hypoglycemic medicines and insulin and is higher in cost and greater in side effect on a human body after long-term use, is quick in effect taking, extract in curative effect, wide in medicinal herb resource ad low in cost, has an effective rate as high as 92% and a low complication occurrence rate, can be used for treating both manifestation and root cause of disease, and has a good long-term effect.
Owner:郝立鹏
New use of wild buckwheat rhizome and wild buckwheat rhizome extract in preparation of hypoglycemic medicine and healthcare food
InactiveCN102727593AStrong alpha-amylase inhibitory activityStrong alpha-glucosidase activityMetabolism disorderPill deliveryAmylase inhibitorsEthyl acetate
Owner:JING BRAND
Features
- R&D
- Intellectual Property
- Life Sciences
- Materials
- Tech Scout
Why Patsnap Eureka
- Unparalleled Data Quality
- Higher Quality Content
- 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com